Images List Premium Download Classic

Monoclonal Antibody

Monoclonal Antibody-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy ...
Oncoquest Inc.
August 10, 2017 - N°20170226221

The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.
Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
Eli Lilly And Company
August 10, 2017 - N°20170224702

The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula i, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti-n3pglu abeta monoclonal antibody.
Combination therapy
Novartis Ag
August 10, 2017 - N°20170224692

The present disclosure relates to pharmaceutical products comprising a combination of (i) a met inhibitor which is inc280 or a pharmaceutically acceptable salt or hydrate thereof and (ii) an egfr inhibitor which is an monoclonal antibody such as cetuximab or panitumumab, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and ...
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3abc and uses thereof
Thomas Jefferson University
August 03, 2017 - N°20170218053

This disclosure pertains to isolated antibodies or antigen binding fragments thereof that specifically bind to the 3abc non-structural protein of foot-and-mouth disease virus (fmdv), wherein the antibodies or antigen binding fragments thereof recognize the amino acid sequence of seq id no: 2, seq id no: 3, seq id no: 4, seq id no: 5, seq id no: 6 or seq id no: 12. Accordingly, this disclosure ...
An anti-ctla4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
Akeso Biopharma, Inc.
August 03, 2017 - N°20170216433

The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of clta4 to b7, relieve the immunosuppression on the body by ctla4, and activate t lymphocytes.
Monoclonal antibody therapy for pancreas cancer
Precision Biologics, Inc.
July 27, 2017 - N°20170210816

The present invention relates to the use of binding equivalents of monoclonal antibody 31. 1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in ...
Novartis Ag
July 20, 2017 - N°20170204374

From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing ror2 or fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.
Muc1* antibodies
Novartis Ag
July 20, 2017 - N°20170204191

The present describes monoclonal antibody to muc1*.
Anti-muc1 antibody or antigen-binding fragment thereof and uses thereof
Medicinal Chemistry Pharmaceuticals, Co., Ltd.
July 13, 2017 - N°20170198056

The present invention provides: an antibody exhibiting specificity for muc1, the antibody having a glycan structure expressed at high levels in cancer cells; a method for manufacturing this antibody; and a novel means and method for the diagnosis and prevention and/or treatment of cancer using this antibody. The present invention is a monoclonal antibody to human muc1, wherein the ...
Antigenic epitopes from ebv gp350/220 and uses thereof
Varolisation-recherche, Limited Partnership
July 06, 2017 - N°20170189517

The present invention relates to a peptide comprising (a) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence pddrtlq (seq id no:1); and (ii) a second domain covalently linked to the first domain and comprising an amino acid sequence having at least 60% sequence similarity with the sequence qnpvylipetvpyikwdn (seq id no:2) or (...
A chronic renal disease diagnostic kit
Wenzhou Medical University
June 29, 2017 - N°20170184593

This invention publicizes a chronic renal disease diagnostic kit, comprised of fgf23 monoclonal antibody, biotin labeling reagent sulfo-nhs-lc-biotin, pbs buffer solution (ph7. 0, 0. 1m), casein saline solution, streptomycin avidin and substrate tmb. The labeling condition is the weight ratio of fgf23 antibody and sulfo-nhs-lc-biotin, which is 1:5-1:12. The dilution ratio of streptomycin avidin is 1:3000. The lowest testing threshold limit value of ...
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
June 29, 2017 - N°20170183418

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a bcma monoclonal antibody, conferring specific immunity against bcma positive cells. The engineered immune cells endowed with such cars are particularly ...
Cd123 specific chimeric antigen receptors for cancer immunotherapy
Cellectis
June 29, 2017 - N°20170183413

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a cd123 monoclonal antibody, conferring specific immunity against cd123 positive cells. The engineered immune cells endowed with such cars are particularly ...
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating atopic dermatitis with il-31 monoclonal antibodies
Zymogenetics, Inc.
June 29, 2017 - N°20170182160

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for il-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human il-31. Cdr regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein vh and vl domains are attached. The sfv molecules can include ...
Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof
Siemens Healthcare Diagnostics Inc.
June 22, 2017 - N°20170176419

A chemiluminescent detection system, as well as kits and microfluidics devices containing same, are disclosed. Methods of using the system, kits, and devices are also disclosed. The first, second, and third antibodies or binding fragments thereof may be provided in any form that allows these antibodies/binding fragments to function in accordance with the presently disclosed and claimed inventive concept(...
Methods of treating neurodegenerative disorders
The Research Foundation For The State University Of New York
June 22, 2017 - N°20170173181

The present disclosure is directed to adeno-associated viral vector monoclonal antibody constructs and compositions thereof, methods of improving locomotor function after spinal cord injury, methods of treating neurodegenerative diseases.
Antibody to mucin 4 (muc4) glycopeptide and uses thereof
Medicinal Chemistry Pharmaceuticals, Co., Ltd.
June 22, 2017 - N°20170173152

The present invention provides: an antibody that has specificity for muc 4 having a sugar chain structure that is expressed at a high level in cancer cells; a glycopeptide that constitutes an antigen that is suitable for producing this antibody; and a new means and method for the diagnosis, prevention, and/or treatment of cancer by means of the aforementioned antibody. ...
Compositions and methods for targeting of the surfactant protein a receptor
The Penn State Research Foundation
June 08, 2017 - N°20170158768

Provided are compositions and methods for use in prophylaxis, therapy and diagnosis of conditions which involve surfactant protein receptors (spr) including the spr for surfactant proteins a (spa). Specific binding partners, including mono-clonal antibodies, for the sp-r210l and sp-r210s isoforms, and methods of using such binding partners are included. Fragments of the monoclonal antibodies, and fusion proteins that ...
Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a ...
Celltrion, Inc.
June 08, 2017 - N°20170158754

The present invention relates to human monoclonal antibodies derived from human b cells present in the blood of patients who had recovered from infection with influenza a viruses, wherein the monoclonal antibodies have neutralizing activity against influenza a viruses. The anti-influenza a virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza a ...
M-csf specific monoclonal antibody and uses thereof
Xoma Technology Ltd.
June 01, 2017 - N°20170152311

M-csf-specific rx1-based or rx-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
Antibodies recognizing alpha-synuclein
Prothena Biosciences Limited
June 01, 2017 - N°20170152310

The invention provides monoclonal antibody 5c1 and related antibodies. The 5c1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include lewy body diseases, such as parkinson's disease, ...
Loading